诺和诺德因收购的Catalent工厂收到FDA警告信。
Novo Nordisk hit with FDA warning letter over acquired Catalent factory
生命科学资讯
生物技术与制药领域的最新动态
诺和诺德药物Amycretin在二期糖尿病试验中减轻体重并降低血糖
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
Novo Nordisk的semaglutide在高度关注的阿尔茨海默病试验中失败了
Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials
#Novo Nordisk#closely-watched Alzheimer#long shot#long shots#Nordisk semaglutide
Novo Nordisk的GLP-1在受到关注的阿尔茨海默病研究中missed目标
Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s studies
#Novo Nordisk#watched Alzheimer#misses goal#heart health#combat neurodegeneration
2025-2033年生物技术市场治疗创新与预测报告：聚焦龙沙、安进、先正达、百康、百健、罗氏、诺华、诺和诺德、辉瑞及西雅图遗传学公司 - ResearchAndMarkets.com - 商业电讯
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and Seagen - ResearchAndMarkets.com - Business Wire
#Therapeutic Innovations#Forecast Report#Featuring Lonza#Novo Nordisk#Market Therapeutic